Taysha Gene Therapies, Inc. SEC Filings

Taysha Gene Therapies reported Q3 2025 results showing higher liquidity and ongoing operating losses. Cash and cash equivalents were $297.3 million, up from $139.0 million at year-end, and total assets reached $316.6 million. The company recorded a Q3 net loss of $32.7 million (basic and diluted net loss per share $0.09) on operating expenses of $34.0 million, driven by research and development of $25.7 million and general and administrative of $8.3 million. Net cash used in operating activities for the first nine months was $66.4 million.

Liquidity improved through a May 2025 underwritten offering that generated $215.6 million in net proceeds and an August 2025 $50.0 million Tranche A term loan with Trinity; the 2023 Trinity loan was repaid at $40.6 million. Deferred revenue of $5.5 million tied to the Astellas Rett option is set to be recognized in Q4 2025 after the option expired unexercised, returning unencumbered rights to TSHA-102. As of November 4, 2025, common shares outstanding were 273,919,373.

Taysha Gene Therapies (TSHA) filed a current report stating it issued a press release titled “Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome.”

The press release, dated October 16, 2025, is furnished as Exhibit 99.1 and incorporated by reference. TSHA-102 is described as the company’s lead program under clinical evaluation for Rett syndrome. No additional terms or financial details are included in this excerpt.

Taysha Gene Therapies (TSHA) filing a Form 144 notifies the planned sale of 10,770 shares of common stock through Maxim Group on Nasdaq with an aggregate market value of $30,479.10. The shares were acquired and vested as RSU awards on 09/22/2025 and settled in stock as consideration for the reporting person’s service. The filing shows 272,794,885 shares outstanding and reports no other sales in the past three months. The filer certifies no undisclosed material adverse information.

Taysha Gene Therapies, Inc. (TSHA) filing a Form 144 notifies a proposed sale of 200,000 common shares through Jefferies LLC on 09/10/2025 with an aggregate market value of $652,000.00. The filing lists total shares outstanding as 272,794,885. Securities to be sold were acquired via vested awards: 158,850 shares from a 01/02/2024 RSU award and 37,106 plus 4,044 shares from vested option grants on 05/31/2023. The form also discloses a prior sale of 57,054 shares on 08/21/2025 for $162,603.90. Several standard filer and issuer contact fields in the notice are blank or not provided.

Nagendran Sukumar, President and Head of R&D and a director of Taysha Gene Therapies (TSHA), reported the disposition of 57,054 shares of the company's common stock on 08/21/2025. The filing states the shares were sold pursuant to a sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock units, at a weighted-average price of $2.85 per share (individual trades ranged $2.841 to $2.865).

After the sale, the reporting person beneficially owns 1,165,289 shares of common stock, held directly. The Form 4 was signed on 08/22/2025 and contains a standard offer to provide breakouts of the amounts sold at each price upon request.

Taysha Gene Therapies (TSHA) CFO Kamran Alam reported a sale of 54,491 shares on 08/21/2025 at a weighted-average price of $2.85 per share. The filing states the shares were sold pursuant to a "sell-to-cover" arrangement to satisfy income tax liabilities from vested restricted stock units, not an open-market discretionary sale. After the transaction Mr. Alam beneficially owned 1,187,603 shares. The filing is a routine Section 16 Form 4 disclosure documenting insider tax-related share disposals and compliance with reporting requirements.

Taysha Gene Therapies (TSHA) filed a Form 144 reporting a proposed sale of 54,491 shares of common stock (RSU award) on 08/21/2025. The shares were a vested RSU grant settled in stock to the reporting person as consideration for continued employment. The broker listed is Maxim Group LLC and the sale is planned on Nasdaq. The filing shows an aggregate market value of $156,389.17 based on the proposed sale and lists 272,794,885 shares outstanding. The filer reports no other sales in the past three months.